🇺🇸 FDA
Pipeline program

Metalyse 5 000 units (25 mg) powder for solution for injection

APHP240911

Phase 3 small_molecule active

Quick answer

Metalyse 5 000 units (25 mg) powder for solution for injection for Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset. is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials